A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-07-31

Summary

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cisplatin; durvalumab; Gemcitabine